Jacobson Mark L. 4
4 · Axsome Therapeutics, Inc. · Filed Sep 22, 2025
Insider Transaction Report
Form 4
Jacobson Mark L.
Chief Operating Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-09-22−10,000→ 35,378 totalExercise: $2.85From: 2019-03-12Exp: 2028-03-12→ Common Stock (10,000 underlying) - Sale
Common Stock
2025-09-22$115.96/sh−10,000$1,159,600→ 0 total - Exercise/Conversion
Common Stock
2025-09-22$2.85/sh+10,000$28,500→ 10,000 total
Footnotes (4)
- [F1]Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.
- [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed.
- [F3]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $115.11 and $116.55.